are less than 5% of all cells, and maturing granulocytes are readily identified.
He returned for a follow-up bone marrow biopsy which showed a residual population of myeloblasts
with persistent cytogenetic abnormalities, consistent with residual disease.
The myeloid stem cells begin with myeloblasts
or myelocytes, which are immature blood cells found only in the bone marrow, then further differentiate into more mature cells (such as the erythrocytes or red blood cells [RBCs]) and polymorphonuclear granulocytes (such as neutrophils, eosinophils, and basophils), monocytes, and platelets (Guyton & Hall, 2000).
The blastic type is made up of myeloblasts
with round-to-oval nuclei, 2 to 4 small nucleoli, fine nuclear chromatin, and a rim of basophilic, finely granular cytoplasm (sometimes containing Auer rods).
To date, we've seen significant reductions in peripheral blood myeloblasts
among some patients with advanced leukemias that were refractory to prior regimens.
in the bone marrow core biopsy, by hematoxylin-eosin morphology or by CD34 immunohistochemical stains, were approximated at 5%.
Bone marrow aspiration showed hypercellularity, with 45% myeloblasts
, 15% promyelocytes, 7% myelocytes, 4% metamyelocytes, 1% eosinophils, 2% neutrophils, 15% lymphocytes, and 11% normoblasts.
Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem cell disorders in which both failure to differentiate and overproliferation in the stem cell compartment result in accumulation of non-functional cells termed myeloblasts
1), (6) A bone marrow aspiration or biopsy is done and AML is diagnosed if there are more than 20% myeloblasts
His bone marrow was hypercellular and appeared to show increased numbers of myeloblasts
with morphologic features most suggestive of early myelodysplastic syndrome (MDS) or incipient AML (Fig.
Preliminary data reported from the phase Ia study have shown that SGN-33 is well-tolerated and has antitumor activity, demonstrated by improved blood counts, decreased transfusion requirements and decreased myeloblasts
in multiple patients with AML or MDS.
A bone marrow biopsy showed 50% infiltration with mast cells and 50% myeloblasts
, confirming the entity of SM-AHNMD (Figure 1).
12) Evidence for the clonal origin of SM-AHNMD from a myeloid stem cell has been shown through targeted fluorescence in situ hybridization analysis for t(8; 21) in leukemic myeloblasts
and neoplastic mast cells in SM AML with t(8; 21)(q22; q22) translocation, for which the fusion product was detected in both cell types.
composed of leukemic myeloblasts
and myeloid precursors.
There is no increase in myeloblasts
or myelodysplastic features.